List of Xtoro drug patents
Xtoro is owned by Merlion Pharms Gmbh.
Xtoro contains Finafloxacin.
Xtoro has a total of 4 drug patents out of which 0 drug patents have expired.
Xtoro was authorised for market use on 17 December, 2014.
Xtoro is available in suspension/drops;otic dosage forms.
Xtoro can be used as treatment of acute otitis externa.
The generics of Xtoro are possible to be released after 21 November, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119859 | MERLION PHARMS GMBH | Methods for treating otic infections |
Jul, 2030
(7 years from now) | |
| US9993483 | MERLION PHARMS GMBH | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(7 years from now) | |
| US8536167 | MERLION PHARMS GMBH | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(8 years from now) | |
| US9504691 | MERLION PHARMS GMBH | Finafloxacin suspension compositions |
Nov, 2033
(10 years from now) | |
Drugs and Companies using FINAFLOXACIN ingredient
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic